TQC2938 / Sino Biopharm - LARVOL DELTA

Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis (clinicaltrials.gov) - P2 | N=136 | Completed | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion • Allergic Rhinitis • Immunology • Inflammation

Efficacy and Safety of TQC2938 Injection in Patients with Moderate-to-severe Seasonal Allergic Rhinitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study (EAACI 2026) - "Administration with TQC2938 exhibited a favorable safety profile. This study provides the first clinical evidence for an anti-ST2 monoclonal antibody in the treatment of SAR, justifying further exploration through large-scale trials."

Clinical • P2 data • Allergic Rhinitis • Immunology • Inflammation • IL33 • ST2

TQC2938-II-01: A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P2 | N=256 | Active, not recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial primary completion date: Dec 2027 ➔ Mar 2027

Enrollment closed • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis (clinicaltrials.gov) - P2 | N=136 | Completed | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Trial primary completion date: Jun 2026 ➔ Sep 2025 | Recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Nov 2025

Trial completion • Trial completion date • Trial primary completion date • Allergic Rhinitis • Immunology • Inflammation

Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis (clinicaltrials.gov) - P2 | N=136 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Allergic Rhinitis • Immunology • Inflammation

Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis (clinicaltrials.gov) - P2 | N=136 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

New P2 trial • Allergic Rhinitis • Immunology • Inflammation

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Human Monoclonal Antibody TQC2938 Targeting the IL-33/ST2 Axis in Healthy Chinese Adults (ATS 2025) - "TQC2938 was well tolerated at all doses administered during the study in healthy Chinese adults. Our results support further clinical development of TQC2938 for COPD and other related diseases mediated by Th2 inflammation."

Clinical • PK/PD data • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Respiratory Diseases • IL33

Three new category 1 drugs with new indications from Zhengda Tianqing were approved for clinical trials [Google translation] (Sina Corp) - "On April 8, three innovative Class 1 antibody drugs of Zhengda Tianqing were approved for clinical trials for new indications. These three new drugs are BCMA/CD3 bispecific antibody TQB2934, EGFR/c-Met bispecific antibody TQB2922 and ST2 monoclonal antibody TQC2938. The newly added indications are the treatment of systemic light chain (AL) amyloidosis in adults, the treatment of advanced malignant tumors in combination with other marketed anti-tumor drugs, and the treatment of seasonal allergic rhinitis."

New trial • Allergic Rhinitis • Amyloidosis • Hematological Malignancies

New breakthrough in targeted therapy - Puyang Oilfield General Hospital adds COPD project and is recruiting subjects [Google translation] (Sohu.com) - "On March 18, 2025, a drug clinical trial of the Department of Respiratory Medicine of our hospital...was successfully launched. The launch meeting was jointly participated by the respiratory medicine research team, the hospital clinical trial institution office, the ethics committee, auxiliary departments, project managers, monitors and clinical research coordinator teams....TQC2938 injection (anti-ST2 humanized monoclonal antibody) independently developed by Zhengda Tianqing targets the ST2 receptor and blocks the IL-33/ST2 signaling pathway, thereby inhibiting the inflammatory response in the pathological process of COPD, reducing airway hyperresponsiveness and lung tissue damage, and providing a new treatment option for COPD patients."

Trial status • Chronic Obstructive Pulmonary Disease

A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P2 | N=256 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

New P2 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Clinical Trial of TQC2938 Injection in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=84 | Active, not recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

New P1 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases